Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 8.6a

Immunosuppression Use for Induction, 2000 to 2009

Recipients with Kidney-Pancreas Transplants

  Year of Transplant
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Transplants 915 891 906 871 881 903 924 864 837 854
With Immunosuppression Info 907 887 900 861 863 891 903 848 826 834
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 3.0% 2.6% 2.8% 1.9% 2.5% 2.4% 0.7% 1.8% 1.5% 1.7%
OKT3 8.2% 3.6% 1.2% 0.3% 0.9% 0.4% 0.8% 1.2% 1.0% 1.4%
Thymoglobulin 22.9% 28.7% 39.1% 48.8% 44.3% 51.6% 61.5% 52.5% 59.9% 63.1%
Zenapax 21.8% 20.0% 16.3% 8.4% 5.0% 4.5% 5.1% 6.6% 6.2% 5.3%
Simulect 27.1% 31.1% 26.4% 16.0% 12.4% 8.2% 5.1% 5.7% 8.4% 10.1%
Campath 0.0% 0.0% 0.0% 7.8% 18.5% 14.8% 11.3% 13.1% 9.8% 11.2%
No Induction Drugs Recorded 26.8% 24.4% 23.4% 20.8% 21.2% 21.2% 18.1% 21.8% 16.6% 12.6%


Source: OPTN/SRTR Data as of October 1, 2010.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.